Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.

Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP.

Clin Ther. 2018 Dec;40(12):2077-2087. doi: 10.1016/j.clinthera.2018.10.011. Epub 2018 Nov 22.

PMID:
30470580
2.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

PMID:
30157388
3.

Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction.

Yarnykh VL, Krutenkova EP, Aitmagambetova G, Repovic P, Mayadev A, Qian P, Jung Henson LK, Gangadharan B, Bowen JD.

AJNR Am J Neuroradiol. 2018 Apr;39(4):618-625. doi: 10.3174/ajnr.A5542. Epub 2018 Feb 8.

4.

Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.

LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, Stone L, Mattson D, Galluzzi A, Fisher TL, Reilly C, Winter LA, Leonard JE, Zauderer M.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e367. doi: 10.1212/NXI.0000000000000367. eCollection 2017 Jul.

5.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A.

Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10.

6.

Fast whole-brain three-dimensional macromolecular proton fraction mapping in multiple sclerosis.

Yarnykh VL, Bowen JD, Samsonov A, Repovic P, Mayadev A, Qian P, Gangadharan B, Keogh BP, Maravilla KR, Jung Henson LK.

Radiology. 2015 Jan;274(1):210-20. doi: 10.1148/radiol.14140528. Epub 2014 Sep 10.

7.

Treatment of multiple sclerosis exacerbations.

Repovic P, Lublin FD.

Neurol Clin. 2011 May;29(2):389-400. doi: 10.1016/j.ncl.2010.12.012.

PMID:
21439448
8.

Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells.

Repovic P, Fears CY, Gladson CL, Benveniste EN.

Oncogene. 2003 Nov 6;22(50):8117-24.

PMID:
14603252
10.
11.
12.

Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor.

Van Wagoner NJ, Oh JW, Repovic P, Benveniste EN.

J Neurosci. 1999 Jul 1;19(13):5236-44.

Supplemental Content

Loading ...
Support Center